TortsProf Blog

Editor: Christopher J. Robinette
Widener Commonwealth Law School

Thursday, July 26, 2007

"Considerable Concern" at FDA About Avandia

Pharmalot has a good overview of the situation, though I question the wisdom of declaring it "AvandiaGate" at this stage. Addition: DrugWonks has an interesting excerpt from the Glaxo submission.


(As usual: I do a small amount of work for pharmaceutical clients.  I have not represented Glaxo, though I've had clients be co-defendants with them.)

Products Liability | Permalink

TrackBack URL for this entry:

Listed below are links to weblogs that reference "Considerable Concern" at FDA About Avandia:


Hey Bill,

I've been referring to the mess as AvandiaGate since it broke, simply because of the confusion over the availability and accessibility of data. Seemed a bit murky at the time (no pun intended, really), and the headline just stuck. Maybe the next one will NissenGate. Who knows?


Posted by: ed | Jul 26, 2007 5:43:00 PM

Reasonable enough. I tend to think that "-gate" gets added to words rather quickly; in this case, even the editorial authors in the journal weren't ready to say you could reach conclusions from the data, which were themselves fairly murky.

Not intended as a slam on you, of course.

Posted by: Bill Childs | Jul 26, 2007 6:13:31 PM

For an interesting set of articles on the evolving Avandia issue and drug safety in general as well as the Patent Reform Bill of 2007, see

Posted by: Ogan Gurel | Jul 27, 2007 10:56:41 AM

Post a comment